Modality
mRNA
MOA
TNFi
Target
CD20
Pathway
Fibrosis
PompeUrothelial CaCTCL
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
Sep 2019
→ Aug 2029
Phase 1Current
NCT08329190
544 pts·CTCL
2019-09→2029-08·Active
NCT03373745
1,834 pts·CTCL
2025-01→TBD·Recruiting
2,378 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-08-243.4y awayInterim· CTCL
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Active
P1
Recruit…
Catalysts
Interim
2029-08-24 · 3.4y away
CTCL
RecruitingActive|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 |